vs

Side-by-side financial comparison of Apyx Medical Corp (APYX) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.

Ispire Technology Inc. is the larger business by last-quarter revenue ($20.3M vs $19.2M, roughly 1.1× Apyx Medical Corp). Apyx Medical Corp runs the higher net margin — -6.8% vs -32.5%, a 25.8% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs -51.5%). Apyx Medical Corp produced more free cash flow last quarter ($-2.8M vs $-4.0M). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs -17.8%).

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

APYX vs ISPR — Head-to-Head

Bigger by revenue
ISPR
ISPR
1.1× larger
ISPR
$20.3M
$19.2M
APYX
Growing faster (revenue YoY)
APYX
APYX
+86.2% gap
APYX
34.7%
-51.5%
ISPR
Higher net margin
APYX
APYX
25.8% more per $
APYX
-6.8%
-32.5%
ISPR
More free cash flow
APYX
APYX
$1.2M more FCF
APYX
$-2.8M
$-4.0M
ISPR
Faster 2-yr revenue CAGR
APYX
APYX
Annualised
APYX
36.8%
-17.8%
ISPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
APYX
APYX
ISPR
ISPR
Revenue
$19.2M
$20.3M
Net Profit
$-1.3M
$-6.6M
Gross Margin
62.6%
17.1%
Operating Margin
0.1%
-33.9%
Net Margin
-6.8%
-32.5%
Revenue YoY
34.7%
-51.5%
Net Profit YoY
71.9%
17.4%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APYX
APYX
ISPR
ISPR
Q4 25
$19.2M
$20.3M
Q3 25
$12.9M
$30.4M
Q2 25
$11.4M
$20.1M
Q1 25
$9.4M
$26.2M
Q4 24
$14.2M
$41.8M
Q3 24
$11.5M
$39.3M
Q2 24
$12.1M
$37.3M
Q1 24
$10.2M
$30.0M
Net Profit
APYX
APYX
ISPR
ISPR
Q4 25
$-1.3M
$-6.6M
Q3 25
$-2.0M
$-3.3M
Q2 25
$-3.8M
$-14.8M
Q1 25
$-4.2M
$-10.9M
Q4 24
$-4.6M
$-8.0M
Q3 24
$-4.7M
$-5.6M
Q2 24
$-6.6M
$-3.5M
Q1 24
$-7.6M
$-5.9M
Gross Margin
APYX
APYX
ISPR
ISPR
Q4 25
62.6%
17.1%
Q3 25
64.4%
17.0%
Q2 25
62.3%
12.3%
Q1 25
60.1%
18.2%
Q4 24
63.0%
18.5%
Q3 24
60.5%
19.5%
Q2 24
61.7%
28.3%
Q1 24
58.1%
20.4%
Operating Margin
APYX
APYX
ISPR
ISPR
Q4 25
0.1%
-33.9%
Q3 25
-6.5%
-8.9%
Q2 25
-22.6%
-72.7%
Q1 25
-32.4%
-40.4%
Q4 24
-21.4%
-17.6%
Q3 24
-31.6%
-13.4%
Q2 24
-45.7%
-9.2%
Q1 24
-64.6%
-18.8%
Net Margin
APYX
APYX
ISPR
ISPR
Q4 25
-6.8%
-32.5%
Q3 25
-15.4%
-10.7%
Q2 25
-33.2%
-73.4%
Q1 25
-44.0%
-41.5%
Q4 24
-32.5%
-19.1%
Q3 24
-40.9%
-14.2%
Q2 24
-54.0%
-9.4%
Q1 24
-74.0%
-19.7%
EPS (diluted)
APYX
APYX
ISPR
ISPR
Q4 25
$-0.12
Q3 25
$-0.06
Q2 25
$-0.26
Q1 25
$-0.19
Q4 24
$-0.14
Q3 24
$-0.10
Q2 24
$-0.19
$-0.07
Q1 24
$-0.22
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APYX
APYX
ISPR
ISPR
Cash + ST InvestmentsLiquidity on hand
$31.7M
$17.6M
Total DebtLower is stronger
$37.5M
Stockholders' EquityBook value
$14.5M
$-7.7M
Total Assets
$66.8M
$84.4M
Debt / EquityLower = less leverage
2.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APYX
APYX
ISPR
ISPR
Q4 25
$31.7M
$17.6M
Q3 25
$25.1M
$22.7M
Q2 25
$29.3M
$24.4M
Q1 25
$31.0M
$23.5M
Q4 24
$31.7M
$34.4M
Q3 24
$28.0M
$37.7M
Q2 24
$32.7M
$35.1M
Q1 24
$37.3M
$39.5M
Total Debt
APYX
APYX
ISPR
ISPR
Q4 25
$37.5M
Q3 25
$37.5M
Q2 25
$37.5M
Q1 25
$37.5M
Q4 24
$37.5M
Q3 24
$37.5M
Q2 24
Q1 24
Stockholders' Equity
APYX
APYX
ISPR
ISPR
Q4 25
$14.5M
$-7.7M
Q3 25
$5.8M
$-1.8M
Q2 25
$7.3M
$604.7K
Q1 25
$10.5M
$14.8M
Q4 24
$14.2M
$24.2M
Q3 24
$11.0M
$30.7M
Q2 24
$14.7M
$34.5M
Q1 24
$20.3M
$35.9M
Total Assets
APYX
APYX
ISPR
ISPR
Q4 25
$66.8M
$84.4M
Q3 25
$57.4M
$96.4M
Q2 25
$58.2M
$102.2M
Q1 25
$60.2M
$115.7M
Q4 24
$64.8M
$132.0M
Q3 24
$60.7M
$129.0M
Q2 24
$65.4M
$122.6M
Q1 24
$70.7M
$108.0M
Debt / Equity
APYX
APYX
ISPR
ISPR
Q4 25
2.58×
Q3 25
6.41×
Q2 25
5.17×
Q1 25
3.57×
Q4 24
2.64×
Q3 24
3.40×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APYX
APYX
ISPR
ISPR
Operating Cash FlowLast quarter
$-2.5M
$-4.0M
Free Cash FlowOCF − Capex
$-2.8M
$-4.0M
FCF MarginFCF / Revenue
-14.6%
-19.9%
Capex IntensityCapex / Revenue
1.4%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-9.1M
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APYX
APYX
ISPR
ISPR
Q4 25
$-2.5M
$-4.0M
Q3 25
$-3.5M
$-1.2M
Q2 25
$-1.2M
$4.7M
Q1 25
$-702.0K
$-12.5M
Q4 24
$-2.9M
$-3.2M
Q3 24
$-4.4M
$3.6M
Q2 24
$-4.3M
$-1.4M
Q1 24
$-6.3M
$3.4M
Free Cash Flow
APYX
APYX
ISPR
ISPR
Q4 25
$-2.8M
$-4.0M
Q3 25
$-4.1M
$-1.2M
Q2 25
$-1.5M
$3.7M
Q1 25
$-757.0K
$-12.7M
Q4 24
$-3.2M
$-3.2M
Q3 24
$-4.6M
$3.3M
Q2 24
$-4.6M
$-2.2M
Q1 24
$-6.4M
$3.3M
FCF Margin
APYX
APYX
ISPR
ISPR
Q4 25
-14.6%
-19.9%
Q3 25
-31.5%
-3.9%
Q2 25
-13.2%
18.6%
Q1 25
-8.0%
-48.4%
Q4 24
-22.4%
-7.7%
Q3 24
-40.0%
8.5%
Q2 24
-38.0%
-5.9%
Q1 24
-62.2%
10.9%
Capex Intensity
APYX
APYX
ISPR
ISPR
Q4 25
1.4%
0.3%
Q3 25
4.0%
0.0%
Q2 25
2.3%
4.8%
Q1 25
0.6%
0.7%
Q4 24
1.7%
0.1%
Q3 24
1.3%
0.7%
Q2 24
2.4%
2.0%
Q1 24
0.3%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons